title: Biotech pharmaceuticals and biotherapy: an overview.
abstract: Broadly, the history of pharmaceutical biotechnology includes Alexander Fleming"s discovery of penicillin in a common mold, in 1928, and the subsequent development-prompted by World War II injuries-of large-scale manufacturing methods to grow the organism in tanks of broth. Pharmaceutical biotechnology has since changed enormously. Two breakthroughs of the late 1970s became the basis of the modern biotech industry: the interspecies transplantation of genetic material, and the fusion of tumor cells and certain leukocytes. The cells resulting from such fusion-hybridomas-replicate endlessly and can be geared to produce specific antibodies in bulk. Modern pharmaceutical biotechnology encompasses gene cloning and recombinant DNA technology. Gene cloning comprises isolating a DNA-molecule segment that corresponds to a single gene and synthesizing ("copying") the segment. Recombinant DNA technology, or gene splicing, comprises altering genetic material outside an organism-for example, by inserting into a DNA molecule a segment from a very different DNA molecule-and making the altered material (recombinant DNA) function in living things. Recombinant DNA technology enables modifying microorganisms, animals, and plants so that they yield medically useful substances, particularly scarce human proteins (by giving animals human genes, for example). This review, however, focuses not on pharmaceutical biotechnology"s methods but on its products, notably recombinant pharmaceuticals. It describes various types of biotech pharmaceuticals, their safety and effectiveness relative to the safety and effectiveness of conventionally produced pharmaceuticals, and the regulation of biotech pharmaceuticals.
authors.affiliation: Georgia Baptist Medical Center, 705 North Crossing Way, Decatur, Georgia 30033-4157, USA.
authors.forename: F M
authors.initials: FM
authors.lastname: Steinberg
authors.forename: J
authors.initials: J
authors.lastname: Raso
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D001709:Biotechnology / Q000379:methods; D001779:Blood Coagulation Factors; D016207:Cytokines; D017277:Drug Approval; D016503:Drug Delivery Systems; D004345:Drug Industry; D004355:Drug Stability; D004798:Enzymes; D005818:Genetic Engineering / Q000379:methods; D015316:Genetic Therapy; D006728:Hormones; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration; D014612:Vaccines
chemical_list: D000911:Antibodies, Monoclonal; D001779:Blood Coagulation Factors; D016207:Cytokines; D004798:Enzymes; D006728:Hormones; D014612:Vaccines